View Entire Collection
By Clinical Topic
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
TUESDAY, Jan. 31 (HealthDay News) -- Long-term use of the diabetes drug metformin is associated with a lower risk of pancreatic cancer only in women, while long-term use of sulfonylureas and insulin are associated with a significantly higher risk of pancreatic cancer, according to a study published online Jan. 31 in the American Journal of Gastroenterology.
Michael Bodmer, M.D., from the University of Basel in Switzerland, and colleagues investigated the correlation between use of diabetes drugs and pancreatic cancer from 2,763 patients diagnosed with pancreatic cancer and 16,578 matched controls (mean age, 69.5 years old; 46.2 percent male).
The researchers found that, although long-term use of metformin (≥30 prescriptions) did not affect the risk of pancreatic cancer overall (adjusted odds ratio [aOR], 0.87; 95 percent confidence interval [CI], 0.59 to 1.29), long-term use was associated with a lower risk in women (aOR, 0.43; 95 percent CI, 0.23 to 0.80). A significantly increased risk of pancreatic cancer was seen with long-term use of sulfonylureas (≥30 prescriptions: aOR, 1.90) and insulin (≥40 prescriptions: aOR, 2.29).
"Use of metformin was associated with a decreased risk of pancreatic cancer in women only, whereas use of sulfonylureas and of insulin was associated with an increased risk of pancreatic cancer," the authors write.
Full Text (subscription or payment may be required)
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top